Today's decision demonstrates Hikma's ability to successfully challenge patents on important medicines and to provide value to our customers and millions of patients across the United States
That´s a good one. If amarin hadn´t done several trials on vascepa, no one would know the benefits of pure EPA. So without vascepa, there wouldn´t be any value to patients, because there wouldn´t be any generics.